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ABSTRACT
Objective: A precise, accurate, simple, and gradient reversed-phase high-performance liquid chromatography (HPLC) method was adapted for the 
determination of abacavir sulfate (ABV) in combination with lamivudine (LMV) having tablet formulations simultaneously. This method developed 
has been validated as per the guidelines of ICH.
Method: Waters HPLC has been used in the method with a column named Zorbax C18 with the dimensions as 4.6 nm×150 mm, 3.5 µm. Phosphate 
buffer (PH - 3.9) was used as Eluent - A, Eluent - B was methanol, and water and methanol (50:50 v/v) were utilized as diluents. The rate of flow was 
1.5 ml/min.
Results: The wavelength of detection has been detected at about 270 nm. Linearity ranges of ABV and LMV were 88–266 µg/ml and 38–116 µg/ml, 
respectively. Retention times of ABV (3.66 min) and LMV (10.71 min) were determined. The values of the study of percentage recovery of ABV and 
LMV were determined to be within 98.3–99.2%.
Conclusion: The estimation of ABV and LMV in all pharmaceutical dosage forms could be performed successfully by employing this method.
Keywords: Abacavir sulfate, Lamivudine, Reversed-phase high-performance liquid chromatography, Validation, Simultaneous estimation, ICH 
guidelines, Pharmaceutical dosage forms.
INTRODUCTION
Chemically, abacavir sulfate (ABV) is (1S-cis)-4-[2-amino-6-
(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol 
sulfate [8-11]. It acts as a nucleoside reverse transcriptase inhibitor. 
It is converted into a metabolite which is active called as carbovir 
triphosphate (CBV-TP) equivalent to deoxyguanosine - 5’ - triphosphate 
(dGTP). CBV-TP acts by hindering the reverse transcriptase activity of 
HIV-1. It competes with a natural substrate called dGTP which leads to 
DNA growth termination.
Chemically, lamivudine (LMV) is 4-amino-1-[(2R, 5S)-2-(hydroxymethyl)-
1,3-oxathiolan-5-yl]pyrimidin-2-one [8-10]. LMV is an antiretroviral 
drug which acts by getting incorporated within viral DNA. HIV reverse 
transcriptase enzyme is inhibited competitively by LMV. This drug serves 
as a chain terminator for the synthesis of DNA.
Literature survey explains that several ultraviolet (UV) 
spectroscopy [1,2], reversed-phase high-performance liquid 
chromatography (RP-HPLC) [3-6] and high-performance thin-layer 
chromatography [7] methods are available for the estimation of ABR and 
LMV. The purpose of the current research is to establish an innovative 
method which gives advanced analytical techniques for identification, 
detection, resolution, accuracy, and precision.
METHODS
Instrumentation
HPLC (make-waters) was used for this method. It has a quaternary 
pump. The column used here was the column named Zorbax luna C18 
with the dimensions as 4.6 mm×150 mm, 3.5 µm. The drugs were 
discovered using UV Detector (Empower - 2 Software). The weighing 
balance used here was Sartorius make. Sonicator (spectra lab) and pH 
meter (polmon) were also used during the method development and 
validation of these drugs.
Reagents and chemicals
HPLC grade Methanol, Milli - Q grade water, analytical reagent 
grade ammonium dihydrogen phosphate, Analytical Reagent Grade 
diammonium hydrogen phosphate, and Analytical Reagent Grade 
trifluoroacetic acid were used. Pure samples of ABR and LMV were 
procured from Hetero labs limited, Hyderabad.
Chromatographic conditions
The analysis was performed using waters HPLC. The method involves 
a column named Zorbax C18 with the dimensions as 4.6 mm×150 mm, 
3.5 µm being used as a stationary phase. The resolution for the drugs 
ABR and LMV was achieved using the mobile phase, phosphate buffer 
(pH -3.9) and methanol and water in 50:50 combination in gradient 
mode. The rate of flow of the eluent was 1.5 ml/min. The runtime was 
20 min. 10 µl was the injection volume and 270 nm was the detection 
wavelength reported. The gradient chromatography conditions were as 
shown in Table 1.
Solution preparation
Phosphate buffer (pH - 3.9)
Ammonium dihydrogen phosphate (2.3 g) and diammonium hydrogen 
phosphate (1.32 g) were dissolved in 1 L of distilled water. The pH was 
maintained at 3.9±0.05 using 50% V/V trifluoro acetic acid (10 ml of 
TFA was transferred into a volumetric flask of 200 ml capacity). The 
volume of the flask was made up to the mark using distilled water. The 
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Preparation of the diluent
Methanol and water were degassed and mixed in the ratio of 50:50. This 
solution was called the diluent.
Preparation of the Standard Solution
The drugs ABV (88 mg) and LMV (38 mg) were transferred into a 50 ml 
standard flask. The flask was sonicated after adding 30 ml of the diluent 
until the drugs dissolve. The volume was made up to the mark with the 
diluent.
Calibration curves
Linearity for the drugs was observed as 100–300 ppm for ABV 
and 40–120 ppm for LMV. The values were in a linear range. The 
linearity plot for ABV and LMV was plotted as response factor versus 
concentration (Figs. 1 and 2 and Tables 2 and 3).
Analysis of tablet formulation
A total of 20 tablets were collected, powdered, and weighed. LMV 
(300 mg) was added to a 100 ml standard flask, 60 ml of diluent was 
then added and kept in a water bath for 30 min at a temperature of 
20–25°C. The flask was diluted with the diluent until it reaches the 
mark. The solution of the sample was centrifuged for 5 min at a speed 
of 5000 rpm. 5 ml of the above solution was added to 200 ml of the 
standard flask and diluted until it reaches the mark using the diluent. 
This was passed through a filter called membrane with 0.45 µm 
dimension. Initially, some ml was discarded.
Procedure
The column was equilibrated for half an hour at 1.5 ml/min flow rate. 
10 µl of the blank solution (diluent) was injected into the system first, 
followed by standard solution (5 injections) and then the sample 
solution. The chromatograms were recorded and the peak responses 
were computed. The typical chromatogram is shown in Fig. 3.
Validation of HPLC method
Specificity
The chromatograms of the mixed standard and sample solutions were 
compared. The specificity of the RP-HPLC method was determined. 
The retention time, tailing factor, and resolution were also evaluated. 
The correlation coefficient was found to be good, and the results were 
shown in Table 1a.
Linearity
A graph was plot between concentration and response for the drugs 
to establish linearity of detector response. At about 50–150% of test 
concentration, the detector responses were linear. The correlation 
coefficient was within the acceptable level. The reports were as reported 
in Tables 2 and 3. The linearity plot was obtained as shown in Figs. 1 and 2.
Table 1: Gradient program of the optimized process
Time (min) Rate of flow Eluent A % Eluent B %
0 min 1.5 ml/min 95 5
10 min 1.5 ml/min 65 35
14 min 1.5 ml/min 20 80
15 min 1.5 ml/min 95 5
20 min 1.5 ml/min 95 5
Table 1a: System suitability
Parameter ABV LMV Acceptance criteria
Tailing factor 1.16 1.16 NMT 2
Resolution (RS) 6.5  >2
Plate number (N) 41549 6089 >2000
Capacity factor 4.54  K>2
Peak summery factor 1.006 0.956 0.9–1.1
ABV: Abacavir sulfate, LMV: Lamivudine
Table 2: Linearity of detection response for ABV
Levels Concentration (ppm) Mean area %RSD
Level 1 88.68 748,537 0.24 
Level 2 141.888 1,203,886
Level 3 177.36 1,494,144
Level 4 177.36 1,494,144 
Level 5 212.832 1,810,109 
Level 6 266.04 2,243,040 0.71 
Slope 8442.76
Y-intercept 1569.6
% 0F Y-intercept 0.11 
Correlation coefficient 0.99991 
ABV: Abacavir sulfate, RSD: Relative standard deviation
Fig. 1: Linearity curve of abacavir sulfate
Fig. 2: Linearity curve of lamivudine
Fig. 3: Typical chromatogram of abacavir sulfate and lamivudine
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Precision
The value of the precision for the proposed method was 0.43% relative 
standard deviation (RSD) ABV and 0.64% RSD LMV. This indicates 
good precision value for the sample being analyzed which is shown in 
Tables 4 and 5.
Accuracy
Recovery studies were used to determine how accurate the developed 
method is at different measures of the test solution usually three which 
were analyzed previously. The standard solution was added to the 
solution containing the drugs (ABR and LMV) within the concentration 
range. The quantity of the recovered drug at each level (n=6) was 
determined, and its percentage recovery was also estimated. The 
recovery studies of ABR and LMV were evaluated to be 98.73 and 
99.06, respectively. The values are given in Tables 5 and 6. The recovery 
studies prove that the current method had no interference with the 
other things which were there in the formulation. The reports were 
shown in Tables 6 and 7.
Robustness
By changing the temperature, flow rate and pH of the given method 
robustness were determined. The method was found to be robust and 
the results was represented in Tables 8 and 9.
System suitability parameters
The system suitability parameters of this method were calculated. 
The values of percentage RSD were found to be within the limits for 5 
replicate injections of ABV and LMV and were found to be 0.48 and 0.65. 
The tailing factors for the drug peaks ABV and LMV were 1.16 and 1.16, 
respectively. The number of theoretical plates for abacavir and LMV was 
41,549 and 68,109 which was found to be within limits. The system 
suitability parameters were calculated. The values were found to be 
within limits and are represented in Table 1.
RESULTS AND DISCUSSION
The current method employs a RP-HPLC procedure using a column 
named Zorbax luna C18 with dimensions 4.6 mm×150 mm and 3.5 µ. 
The eluent used here was phosphate buffer (pH - 3.9) and methanol 
and water (50:50). To select the wavelength for sampling, the drugs 
were measured using UV-visible spectrophotometer in 200–400 nm 
wavelength range. After scanning the spectrum of each one of the drugs, 
270 nm was finally selected as a wavelength suitable for the estimation 
of the drugs of our interest. The resolution for ABR and LMV was 
achieved in 20 min (runtime) with a given flow rate (1.5 ml/min) and 
was found to the best.
The linearity values for ABV and LMV were found to be within the 
range (100–300 ppm and 40–120 ppm, respectively). The method of 
interest was evaluated for accuracy by addition of a standard drug 
solution containing the drugs within the concentration range of ABV 
and for LMV, and it was added to the previously analyzed test solution. 
The recovery studies for ABV and LMV were 98.73% and 99.06%, 
respectively. The method of interest was evaluated for precision and the 
percentage RSD values were reported as 0.43 for ABV and 0.64 for LMV. 
This indicates that a good precision value for the sample was reported. 
By changing the temperature, flow rate or pH of the given method, the 
suitability parameters of the system were observed to be within limits. 
Hence, the method is said to be robust. The validation parameters such 
as selectivity and sensitivity of our method of interest were proved to 
be acceptable because the parameters such as tailing factor, the number 
of theoretical plates, separation factor, resolution, and statistical 
parameters and results of the analysis were found be within limits.
Table 3: Linearity of detection response for LMV
Levels Concentration (ppm) Mean area % RSD 
Level 1 38.71 696,053 0.59 
Level 2 61.936 1,123,050   
Level 3 77.42 1,389,538   
Level 4 77.42 1,389,538   
Level 5 92.904 1,695,335   
Level 6 116.13 2,106,171 0.97 
Slope 18250.56 
Y-intercept -1301.12 
% 0F Y-intercept -0.94 
Correlation coefficient 0.99982 
LMV: Lamivudine, RSD: Relative standard deviation
Table 4: Method precision for ABV
Sample no. Peak area % Assay 
1 1,537,605 102.5 
2 1,530,101 102 
3 1,533,166 102.2 
4 1,542,077 102.9 
5 1,522,358 101.5 
6 1,533,156 102.2 
  Mean 102.2 
  SD 0.47 
  % RSD 0.46 
ABV: Abacavir sulfate, RSD: Relative standard deviation
Table 5: Method precision for LMV
Sample no. Peak area % Assay 
1 1,347,989 100 
2 1,336,374 99.1 
3 1,339,601 99.3 
4 1,353,322 100.4 
5 1,334,982 99 
6 1,354,089 100.4 
  Mean 99.7 
  SD 0.64 
  % RSD 0.64 
LMV: Lamivudine, RSD: Relative standard deviation
Table 6: Accuracy data for ABV
Concentration of spiked 
level(%)
Sample no Amount added Amount found % Recovery Mean SD % RSD 
50 1 84.8 83.25 98.2 98.9 1.04 1.05 
2 85.03 85.08 100.1 
3 84.86 83.47 98.4 
100 1 172.83 171.37 99.2 99.0 0.62 0.63 
2 172.8 171.88 99.5 
3 173.14 170.17 98.3 
150 1 255.15 255.15 98.1 98.3 0.40 0.41 
2 259.71 256.69 98.8 
3 259 254.15 98.1 
ABV: Abacavir sulfate, RSD: Relative standard deviation, SD: Standard deviation
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Table 7: Accuracy data for LMV
Concentration of spiked 
level (%)
sample no Amount of the drug 
added (mg)







50 1 38.2 37.45 98.0 99.2 1.11 1.12 
2 38.06 38.13 100.2 
3 38.18 37.97 99.4 
100 1 75.97 75.64 99.6 99.2 0.55 0.55 
2 76.19 75.79 99.5 
3 75.96 74.92 98.6 
150 1 113.94 112.46 98.7 98.8 0.40 0.40 
2 113.36 112.44 99.2 
3 113.71 111.9 98.4 
LMV: Lamivudine, RSD: Relative standard deviation, SD: Standard deviation
Table 8: ABV robustness
Parameters Results RT (min) Mean peak area (n=5) of abacavir % RSD
Flow rate 1.5 ml/min  10.701 1,543,762 0.04 
Flow rate 1.4 ml/min 12.359 1,623,612 0.34 
Flow rate 1.6 ml/min 9.281 1,183,133 0.07 
Column temperature 45°C 10.452 1,482,427 0.06 
Column temperature 55°C 10.679 1,468,953 0.13 
Buffer Ph 3.7 11.249 1,543,198 0.10 
Buffer pH 4.2 10.129 1,574,944 0.39 
ABV: Abacavir sulfate, RT: Retention time, RSD: Relative standard deviation, SD: Standard deviation
Table 9: Results of robustness (LMV)
Parameters Results RT (min) Mean peak area (n=5) of LMV % RSD
Flow rate (1.5 ml/min, 50°C) 3.675 1,352,313 0.50 
Flow rate 1.4 ml/min 4.592 1,554,365 0.42 
Flow rate 1.6 ml/min 2.973 1,096,323 0.12 
Column temperature 45°C 3.842 1,474,128 0.04 
Column temperature 55°C 3.290 1,496,459 0.07 
Buffer pH 3.7 4.702 1,387,432 0.14 
Buffer pH 4.2 3.482 1,453,421 0.37 
LMV: Lamivudine, RT: Retention time, RSD: Relative standard deviation, SD: Standard deviation
CONCLUSION
The current work explains a simple, robust, economical, and non-
interfering simultaneous method for the evaluation of ABV and LMV 
using RP-HPLC technique. The present procedure was observed as a 
simple, accurate, economic, reproducible, and precise while performing 
the analysis of drug formulations having both the drugs.
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